BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 25573307)

  • 21. [Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Han TT; Xu LP; Liu DH; Liu KY; Zhang XH; Chen H; Chen YH; Han W; Wang FR; Wang Y; Wang JZ; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):651-4. PubMed ID: 23978013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence, risk factors, and clinical outcomes associated with Epstein-Barr virus-DNAemia and Epstein-Barr virus-associated disease in patients after haploidentical allogeneic stem cell transplantation: A single-center study.
    Zhou L; Gao ZY; Lu DP
    Clin Transplant; 2020 Jun; 34(6):e13856. PubMed ID: 32170765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML.
    Cao XY; Chen JQ; Wang H; Ma W; Liu WW; Zhang FF; Xue S; Dong L; Liu T; Zhao XZ; Liu CC; Xu X; He Y; Wang L; Wang JL
    Ann Med; 2023 Dec; 55(1):388-400. PubMed ID: 36629738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation.
    Xuan L; Jiang X; Sun J; Zhang Y; Huang F; Fan Z; Guo X; Dai M; Liu C; Yu G; Zhang X; Wu M; Huang X; Liu Q
    Transplantation; 2013 Sep; 96(6):560-6. PubMed ID: 23842192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation.
    Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yan CH; Liu ZY; Huang XJ
    Ann Hematol; 2019 Aug; 98(8):1877-1883. PubMed ID: 31144019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease.
    Gotoh M; Yoshizawa S; Katagiri S; Suguro T; Asano M; Kitahara T; Akahane D; Okabe S; Tauchi T; Ito Y; Ohyashiki K
    Transpl Infect Dis; 2014 Jun; 16(3):440-9. PubMed ID: 24810656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Quantitative monitoring of blood cytomegalovirus after allogeneic hematopoietic stem cell transplantation and its clinical significance].
    Qiu ZX; Wang MJ; Wang LH; Sun YH; Xu WL; Liu W; Ou JP; Dong YJ; Li Y; Liang ZY; Cen XN; Ren HY
    Zhonghua Nei Ke Za Zhi; 2012 May; 51(5):371-5. PubMed ID: 22883336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of CMV and EBV on Immune Recovery After Allogeneic Hematopoietic Cell Transplantation in Children.
    Pukownik E; Kubicka M; Kurylo-Rafinska B; Debski R; Galazka P; Czyzewski K; Krenska A; Bartoszewicz N; Demidowicz E; Marjańska A; Dziedzic M; Pogorzala M; Wysocki M; Styczynski J
    Anticancer Res; 2018 Oct; 38(10):6009-6013. PubMed ID: 30275233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation.
    Bordon V; Padalko E; Benoit Y; Dhooge C; Laureys G
    Pediatr Transplant; 2012 Mar; 16(2):144-50. PubMed ID: 22288846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Features of Epstein-Barr Virus and Cytomegalovirus Reactivation in Acute Leukemia Patients After Haplo-HCT With Myeloablative ATG-Containing Conditioning Regimen.
    Ru Y; Zhu J; Song T; Ding Y; Zhu Z; Fan Y; Xu Y; Sun A; Qiu H; Jin Z; Tang X; Han Y; Fu C; Chen S; Ma X; Chen F; Chen J; Wu D
    Front Cell Infect Microbiol; 2022; 12():865170. PubMed ID: 35651756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation.
    Rustia E; Violago L; Jin Z; Foca MD; Kahn JM; Arnold S; Sosna J; Bhatia M; Kung AL; George D; Garvin JH; Satwani P
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1646-1653. PubMed ID: 27252110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
    Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis.
    Düver F; Weißbrich B; Eyrich M; Wölfl M; Schlegel PG; Wiegering V
    PLoS One; 2020; 15(2):e0228451. PubMed ID: 32017805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation.
    Jaskula E; Dlubek D; Sedzimirska M; Duda D; Tarnowska A; Lange A
    Transplant Proc; 2010 Oct; 42(8):3273-6. PubMed ID: 20970670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cytomegalovirus infection monitoring in patients with long-term survival after allogeneic hematopoietic stem cell transplantation].
    Chen L; Luo Y; Hu Y; Tan Y; Zhao Y; Fan J; Huang H
    Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3145-9. PubMed ID: 25573309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABO Blood Type Incompatibility Is Not a Risk Factor of Outcomes for Acute Myeloid Leukemia (AML) Patients After Unmanipulated Haplo-identical Peripheral Blood Hematopoietic Stem Cell Transplantation.
    Yang N; Guan L; Liu Z; Ding Y; Zhu C; Luo L; Wang F; Fang S; Gao Z; Gu Z; Gao C
    Ann Transplant; 2019 Jun; 24():350-358. PubMed ID: 31197126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study.
    Liu X; Wu M; Peng Y; Chen X; Sun J; Huang F; Fan Z; Zhou H; Wu X; Yu G; Zhang X; Li Y; Xiao Y; Song C; Xiang AP; Liu Q
    Cell Transplant; 2014; 23(9):1087-98. PubMed ID: 23294601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34
    Huang YT; Kim SJ; Lee YJ; Burack D; Nichols P; Maloy M; Perales MA; Giralt SA; Jakubowski AA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1759-1766. PubMed ID: 28668490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Quantitative monitoring of mononucleated cell Epstein-Barr virus (EBV)-DNA for predicting EBV associated lymphoproliferative disorders after stem cell transplantation.].
    Wang LH; Ren HY; Sun YH; Qiu ZX; Cen XN; Ou JP; Xu WL; Wang MJ; Wang WS; Li Y; Dong YJ; Yin Y; Liang ZY
    Zhonghua Xue Ye Xue Za Zhi; 2010 Feb; 31(2):73-6. PubMed ID: 20302791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.